Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare uveal melanoma that arises from the ciliary body. Patients may present with blurred vision, visual field loss, floaters, and ocular pain. The prognosis is usually poor.
Biomarker and diagnostic research for malignant ciliary body melanoma has been reported in the published literature.
1 clinical trial registered. Interventions under study include drug therapy, other interventions, and procedural interventions. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
154 publications have been identified in PubMed for malignant ciliary body melanoma. Research spans Basic Science / Preclinical (26%), Review / Meta-Analysis (21%), and Epidemiology / Natural History (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 40 |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 7:14 PM UTC
Research summaries | 33 | 21% |
Disease patterns and progression | 26 | 17% |
Clinical study results | 19 | 12% |
Patient case studies | 13 | 8% |
New treatment approaches | 12 | 8% |
Testing and diagnosis research | 11 | 7% |
Gutiérrez-Cuesta A (2026). [PMID: 42082324](https://pubmed.ncbi.nlm.nih.gov/42082324/). *Br J Ophthalmol*. [Diagnostic / Biomarker]
Chava S (2026). [PMID: 41366520](https://pubmed.ncbi.nlm.nih.gov/41366520/). *EMBO molecular medicine*. [Basic Science / Preclinical]
Shields CL (2026). [PMID: 42153890](https://pubmed.ncbi.nlm.nih.gov/42153890/). *Retina*. [Clinical Trial Publication]
Hiong A (2026). [PMID: 41633932](https://pubmed.ncbi.nlm.nih.gov/41633932/). *Clinical & experimental ophthalmology*. [Basic Science / Preclinical]
Atlıhan YS (2026). [PMID: 41360327](https://pubmed.ncbi.nlm.nih.gov/41360327/). *Archivos de la Sociedad Espanola de Oftalmologia*. [Clinical Trial Publication]
Mukundan A (2026). [PMID: 41316839](https://pubmed.ncbi.nlm.nih.gov/41316839/). *Ocular immunology and inflammation*. [Review / Meta-Analysis]
Nahon-Estève S (2026). [PMID: 41633531](https://pubmed.ncbi.nlm.nih.gov/41633531/). *Canadian journal of ophthalmology. Journal canadien d'ophtalmologie*. [Epidemiology / Natural History]
Dalvin LA (2026). [PMID: 41808271](https://pubmed.ncbi.nlm.nih.gov/41808271/). *Expert opinion on drug discovery*. [Clinical Trial Publication]
Miano DI (2026). [PMID: 42153885](https://pubmed.ncbi.nlm.nih.gov/42153885/). *Retin Cases Brief Rep*. [Case Report / Case Series]
On S (2026). [PMID: 41681877](https://pubmed.ncbi.nlm.nih.gov/41681877/). *Cancers*. [Basic Science / Preclinical]